CD19-directed Cytolytic Antibody [EPC]

858 reported adverse events

Drugs of this class: INEBILIZUMAB

These side effects are most commonly reported by patients taking drugs of the CD19-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 NEUROMYELITIS OPTICA SPECTRUM DISORDER 130
1 OFF LABEL USE 76
2 HEADACHE 50
3 URINARY TRACT INFECTION 44
4 FATIGUE 39
5 NAUSEA 38
6 MYASTHENIA GRAVIS 37
7 PNEUMONIA 36
8 COVID-19 32
9 PAIN 31
See all common reactions for CD19-directed Cytolytic Antibody [EPC]

Drugs of the CD19-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 NEUROMYELITIS OPTICA SPECTRUM DISORDER 130 0.0964
1 IMMUNOGLOBULIN G4 RELATED DISEASE 12 0.0376
2 T-LYMPHOCYTE COUNT DECREASED 6 0.0088
3 IMMUNOGLOBULINS DECREASED 8 0.0058
4 MYASTHENIA GRAVIS 37 0.0046
5 MYELITIS TRANSVERSE 6 0.0043
6 CD4 LYMPHOCYTES DECREASED 7 0.0033
7 MYELITIS 5 0.0032
8 B-LYMPHOCYTE COUNT DECREASED 4 0.0029
9 BLOOD IMMUNOGLOBULIN G DECREASED 7 0.0028
See all enriched reactions for CD19-directed Cytolytic Antibody [EPC]